Zobrazeno 1 - 5
of 5
pro vyhledávání: '"H. Mark Lin"'
Autor:
Daniel J. George, H. Mark Lin, Shih-Yuan Lee, Susan Moran, Justine Y. Bruce, Charles J. Ryan, Joshi J. Alumkal, Hans J. Hammers, M. Dror Michaelson, Paul G. Corn, Maha Hussain
Supplementary Table S1- Number of patients with 1-4 and {greater than or equal to}5 CTCs per 7.5mL of whole blood at baseline, and at 3, 6 and 12 months. Supplementary Table S2- Biochemical markers of bone turnover and bone mineral density (BMD).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49c89d8221c1c8f8fc419178bbed2bff
https://doi.org/10.1158/1078-0432.22454825.v1
https://doi.org/10.1158/1078-0432.22454825.v1
Autor:
Susan Moran, Shih Yuan Lee, Hans J. Hammers, H. Mark Lin, Charles J. Ryan, Paul G. Corn, Maha Hussain, Justine Yang Bruce, Joshi J. Alumkal, Daniel J. George, M. Dror Michaelson
Publikováno v:
Clinical Cancer Research. 20:4218-4227
Purpose: Orteronel (TAK-700) is an investigational, nonsteroidal, oral, inhibitor of androgen synthesis with greater specificity for 17,20-lyase than for 17α-hydroxylase. We investigated orteronel without steroids in patients with nonmetastatic cast
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56915c9ba89718e3729c08caf637bf53
https://doi.org/10.1158/1078-0432.ccr-14-0356
https://doi.org/10.1158/1078-0432.ccr-14-0356
Autor:
H. Mark Lin, Josephine Park, Oliver Sartor, David B. MacLean, Bruce J.O. Wong, Kathleen Beusterien, Emuella Flood, Iain J. Webb
Publikováno v:
Clinical genitourinary cancer. 13(2)
Introduction This study aimed to examine the impact of advanced prostate cancer and its treatments on patients' perceptions of their health and to better understand concerns not captured by currently available health-related quality of life (HRQL) in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d02b3185e364a670f6954da6cf7bd235
https://pubmed.ncbi.nlm.nih.gov/25262852
https://pubmed.ncbi.nlm.nih.gov/25262852
Autor:
H. Mark Lin, P. Mortimer, Shih-Yuan Lee, Charles J. Ryan, Susan Moran, Maha Hussain, Justine Yang Bruce, Joshi J. Alumkal, David B. MacLean, Paul G. Corn, M. Dror Michaelson, Hans J. Hammers, Yanyan Zhu, Daniel J. George, Hongliang Shi
Publikováno v:
Journal of Clinical Oncology. 31:5076-5076
5076 Background: Ortl is a selective, non-steroidal, oral 17,20-lyase inhibitor. Due to its lower inhibition of 17α-hydroxylase vs 17,20-lyase, ortl may allow steroid-free dosing. Ortl 300 mg BID was studied in nmCRPC patients (pts). Methods: Pts wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c98c0fc60eb67a31f72d645919e3eea6
https://doi.org/10.1200/jco.2013.31.15_suppl.5076
https://doi.org/10.1200/jco.2013.31.15_suppl.5076
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.